Rezolute, Inc. (RZLT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.58+0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RZLT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||||||||||
| R&D Expenses | 59.8 | 61.5 | 55.7 | 43.8 | 32.5 | 15.0 | 14.5 | 19.1 | 17.3 | 12.1 | 9.4 | 4.7 | 0.0 | 0.0 | 0.0 |
| Operating Income | (87.3) | (79.9) | (70.4) | (56.0) | (41.8) | (22.9) | (20.5) | (25.9) | (28.7) | (20.3) | (15.0) | (10.7) | (5.2) | (6.1) | — |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | — | — | — | — | 0.4 | 0.0 | 5.0 | 0.7 | 0.0 | 0.0 | 0.0 | 4.2 | 0.6 | — |
| Interest & Investment Income | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| Net Interest Expenses | — | — | — | — | — | — | — | — | 0.7 | 0.0 | 0.0 | 0.0 | 4.2 | — | — |
| Other Non-Operating Income / Expenses | 5.8 | 5.5 | 2.0 | 4.2 | 0.8 | 2.0 | 0.2 | (4.5) | (1.1) | 0.0 | 0.0 | (0.7) | (4.6) | (0.6) | — |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | |||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | 2.3 | — | — | — | — | — | — | — |
| Net Income | (81.5) | (74.4) | (68.5) | (51.8) | (41.1) | (20.9) | (20.3) | (30.4) | (29.9) | (20.3) | (14.9) | (11.4) | (9.7) | (6.7) | (0.8) |
| Per Share | |||||||||||||||
| Basic EPS | (0.78) | (0.98) | (1.33) | (1.01) | (2.26) | (2.72) | — | — | — | — | — | — | (1.04) | (1.08) | — |
| Diluted EPS | (0.78) | (0.98) | (1.33) | (1.01) | (2.32) | (2.72) | — | — | — | — | — | — | (1.04) | (1.08) | — |
| Basic Weighted Avg Shares | 104.0 | 76.0 | 51.5 | 51.2 | 18.2 | 7.7 | — | — | — | — | — | — | 9.4 | — | — |
| Diluted Weighted Avg Shares | 104.0 | 76.0 | 51.5 | 51.2 | 19.5 | 7.7 | — | — | — | — | — | — | 9.4 | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | (79.9) | (70.4) | (56.0) | (41.8) | (22.9) | (20.5) | (25.9) | — | — | — | — | (5.2) | — | — |
| EBIT | (87.3) | (79.9) | (70.4) | (56.0) | (41.8) | (22.9) | (20.5) | (25.9) | (28.7) | (20.3) | (15.0) | (10.7) | (5.2) | (6.1) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.